Video
Dr. Jagannath on Mechanism of Action of Selinexor in Myeloma
Author(s):
Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the mechanism of action of selinexor and its efficacy in multiple myeloma and other tumor types.
Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the mechanism of action of selinexor and its efficacy in multiple myeloma and other tumor types.
Selinexor is an orally available selective inhibitor of a nuclear export that blocks the nuclear export protein CRM1, which is responsible for exporting all of the tumor inhibitory molecules. These cells then will then go into arrest or death, Jagannath explains.
There is great excitement with this agent because it has shown impact in multiple myeloma, acute myeloid leukemia, and even solid tumors, he adds. Selinexor has already been combined with bortezomib (Velcade), carfilzomib (Kyprolis), and soon with immunomodulatory agents.
